false 0000815094 0000815094 2019-08-07 2019-08-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2019

 

ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-09585

04-2743260

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

22 Cherry Hill Drive
Danvers, Massachusetts 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

ABMD

The NASDAQ Stock Market LLC

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    

 

 

 



Item 5.07

Submission of Matters to a Vote of Security Holders.

On August 7, 2019, ABIOMED, Inc. (the Company ) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”). The holders of 40,856,318 shares of common stock were present or represented by proxy at the meeting. Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter as reported by the inspector of elections.

Proposal One: Election of Directors

The Company s stockholders elected each of Michael R. Minogue and Martin P. Sutter as a member of the Company s board of directors as a Class III director to serve a three-year term expiring at the 2022 Annual Meeting of Stockholders and until his successor is duly elected and qualified ( or until his earlier removal, death or resignation) , with the votes cast and broker non-votes as follows:

Nominee

 

 

 

Votes For

 

 

Votes Withheld

 

 

Broker Non-Votes

 

Michael R. Minogue

 

 

 

 

33,791,919

 

 

 

1,333,097

 

 

 

0

 

Martin P. Sutter

 

 

 

 

31,510,183

 

 

 

3,614,833

 

 

 

0

 

 

Proposal Two: Non-Binding, Advisory Vote on Executive Compensation

The Company s stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company s named executive officers (as disclosed in the proxy statement filed in connection with the Annual Meeting), with the votes cast, abstentions and broker non-votes as follows:

Votes For

 

 

Votes Against

 

 

Abstentions

 

 

Broker Non-Votes

 

 

18,333,903

 

 

 

15,575,542

 

 

 

1,215,571

 

 

 

5,731,302

 

Proposal Three: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

At the Annual Meeting, the Company s stockholders ratified the appointment of Deloitte & Touche LLP as the Company s independent registered public accounting firm for the fiscal year ending March 31, 2020, with the votes cast, abstentions and broker non-votes as follows:

 

Votes For

 

 

Votes Against

 

 

Abstentions

 

 

Broker Non-Votes

 

 

40,219,111

 

 

 

617,744

 

 

 

19,463

 

 

 

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

ABIOMED, Inc.

 

 

 

 

 

 

 

 

By:

 

/s/ Marc A. Began

 

 

 

 

 

 

Marc A. Began

Vice President, General Counsel and Secretary

(Authorized Signatory)

 

Date: August 9, 2019

 

 

 

 

 

 

 

 

 

ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ABIOMED Charts.
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ABIOMED Charts.